Search

Displaying results 3731 - 3740 of 5897 in total
  1. Drug

    Trichloroethylene

    go.drugbank.com/drugs/DB13323
    Approved

    Trichloroethylene is a halocarbon commonly used as an industrial solvent, not to be confused with the similar 1,1,1-trichloroethane, also known as chlorothene.

  2. Drug

    Protirelin

    go.drugbank.com/drugs/DB09421
    Approved

    Although not currently available in any FDA-approved product, protirelin is a component of the TRH Test where it is used to test the response of the anterior pituitary gland in conditions such as secondary

  3. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.

  4. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. … It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha.

  5. Drug

    QRX-411

    go.drugbank.com/drugs/DB17868
    Experimental

    QRX-411 is a first-in-class RNA-based oligonucleotide designed to restore wild-type USH2A mRNA, leading to the production of the functional USH2A protein. … It addresses the underlying cause of Usher syndrome due to the c.7595-2144A>G mutation in the _USH2A_ gene.[L46777]

  6. Drug

    Oregovomab

    go.drugbank.com/drugs/DB04964
    Investigational

    Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.

  7. Drug

    VP025

    go.drugbank.com/drugs/DB05133
    Experimental

    It is considered to be a systemic anti-inflammatory and neuroprotective agent. … It also shows the ability to reduce inflammation across the blood-brain barrier and improve correlates of memory and learning function.

  8. Drug

    R112

    go.drugbank.com/drugs/DB06252
    Experimental

    R112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.

  9. Drug

    PTI-801

    go.drugbank.com/drugs/DB05300
    Investigational

    PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone.

  10. Drug

    Abivertinib

    go.drugbank.com/drugs/DB15327
    Investigational

    [L17388] Abivertinib's potential to depress cytokine production has led to its investigation in the treatment of hospitalized patients with moderate-to-severe COVID-19. … The study is expected to be completed in March 2021.[L17398]